

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUNPHARMA
复星医药

上海復星醫藥(集團)股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
*(a joint stock limited company incorporated in the People's Republic of
China with limited liability)*
(Stock Code: 02196)

FOSUN 复星
復星國際有限公司
FOSUN INTERNATIONAL LIMITED
(Incorporated in Hong Kong with limited liability)
(Stock Code: 00656)

JOINT PROGRESS ANNOUNCEMENT — PROPOSED ADOPTION OF MANAGEMENT SHARE OPTION SCHEME OF SISRAM MEDICAL

This joint announcement is made by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“**Fosun Pharma**”) and Fosun International Limited (“**Fosun International**”).

References are made to the joint announcements of Fosun Pharma and Fosun International dated 26 April 2013 and 28 May 2013 (the “**Joint Announcements**”) in relation to, among other things, the acquisition by Sisram Medical of the equity interest in Alma Lasers. Unless otherwise indicated, capitalized terms used herein shall have the same meanings as defined in the Joint Announcements.

As disclosed in the Joint Announcements, pursuant to the Share Purchase Agreement, Sisram Medical will establish a management share option scheme (the “**Sisram Medical Plan**”), through which certain share options (the “**Sisram Options**”) will be granted by Sisram Medical to certain existing and the newly joined management members of Alma Lasers (the “**Sisram Grantees**”).

On 26 August 2014, the Board of Fosun Pharma and the Board of Fosun International resolved respectively that (i) subject to the approvals of the shareholders of Fosun Pharma and Fosun International, the Sisram Medical Plan will be adopted by Sisram Medical; and (ii) subject to the Sisram Medical Plan becoming effective, Sisram Options will be granted under the Sisram Medical Plan. Pursuant to the Sisram Medical Plan, the total number of Shares which may be issued upon exercise of all Sisram Options to be granted under the Sisram Medical Plan is 106,500 Shares (of which 6,500 shares are reserved for adjustment), expected to represent approximately 14.49% of the issued share capital of Sisram Medical at the date of approval of Sisram Medical Plan.

It is proposed that Sisram Options under the Sisram Medical Plan be granted to the Sisram Grantees to subscribe, at a purchase price of approximately US\$201.25 per Share, which is equivalent to the value per share of Sisram Medical in line with the consideration reflecting its investment in the acquisition of the 95.16% equity interest in Alma Lasers, for an aggregate of 100,000 shares in the share capital of Sisram Medical, expected to represent approximately 13.61% of the existing issued share capital of Sisram Medical and approximately 11.98% of the issued share capital of Sisram Medical as enlarged by the Sisram Options (assuming that all options are fully exercised before adjustment).

The Sisram Grantees of the Sisram Options under the Sisram Medical Plan include (i) 96 named individuals being the founders of Alma Lasers and/or existing senior management members of Alma Lasers; and (ii) the other Sisram Grantees being the other employees of and service providers to Alma Lasers, as determined by the board of directors of Sisram Medical.

The establishment of the aforesaid Sisram Medical Plan will be subject to the approval of the shareholders of both Fosun Pharma and Fosun International. A circular containing, among other things, details regarding the Sisram Medical Plan will be dispatched to the shareholders of Fosun Pharma and Fosun International in due course.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

By order of the Board
Fosun International Limited
Guo Guangchang
Chairman

Shanghai, PRC
26 August 2014

As at the date of this announcement, the executive directors of Fosun Pharma are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive directors of Fosun Pharma are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive directors of Fosun Pharma are Mr. Han Jiong, Dr. Zhang Weijiong, Mr. Li Man-kiu Adrian David and Mr. Cao Huimin.

As at the date of this announcement, the executive directors of Fosun International are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Ding Guoqi, Mr. Qin Xuetao and Mr. Wu Ping; the non-executive director of Fosun International is Mr. Fan Wei, and the independent non-executive directors of Fosun International are Mr. Zhang Shengman, Mr. Andrew Y. Yan, Mr. Zhang Huaqiao and Mr. David T. Zhang.

* *for identification purposes only*